Celltrion Healthcare 将来の成長

Future 基準チェック /46

Celltrion Healthcare利益と収益がそれぞれ年間63.3%と17.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に13.7% 62.7%なると予測されています。

主要情報

63.3%

収益成長率

62.7%

EPS成長率

Healthcare 収益成長	19.0%
収益成長率	17.2%
将来の株主資本利益率	13.7%
アナリストカバレッジ	Good
最終更新日	12 Jan 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

KOSDAQ:A091990 - アナリストの将来予測と過去の財務データ ( )KRW Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	3,243,700	371,178	109,667	203,533	9
12/31/2024	2,796,111	276,422	169,633	290,500	9
12/31/2023	2,335,125	166,067	38,000	-14,550	4
9/30/2023	2,218,023	43,133	125,162	130,923	N/A
6/30/2023	2,066,847	135,951	-42,286	-38,061	N/A
3/31/2023	2,060,053	157,644	210,387	212,159	N/A
12/31/2022	1,972,188	147,178	200,533	202,119	N/A
9/30/2022	2,036,930	237,067	81,334	85,204	N/A
6/30/2022	1,949,646	140,048	108,060	122,236	N/A
3/31/2022	1,863,891	164,644	-180,959	-158,041	N/A
12/31/2021	1,804,486	152,567	-198,120	-175,312	N/A
9/30/2021	1,585,653	167,523	-161,698	-141,655	N/A
6/30/2021	1,639,954	213,010	-203,646	-191,967	N/A
3/31/2021	1,626,987	195,722	-61,689	-58,698	N/A
12/31/2020	1,627,597	240,407	-25,605	-22,608	N/A
9/30/2020	1,554,163	249,216	-156,588	-153,565	N/A
6/30/2020	1,372,783	173,262	-200,974	-200,156	N/A
3/31/2020	1,237,266	135,315	-192,454	-191,682	N/A
12/31/2019	1,100,878	64,962	-164,433	-163,839	N/A
9/30/2019	976,014	-42,023	-128,387	-128,208	N/A
6/30/2019	906,649	-45,782	37,692	38,023	N/A
3/31/2019	805,635	-43,278	-83,143	-82,781	N/A
12/31/2018	713,487	11,386	-185,406	-184,228	N/A
9/30/2018	989,193	175,707	-192,348	-190,910	N/A
6/30/2018	945,767	178,499	-349,535	-347,847	N/A
3/31/2018	991,440	238,447	-254,164	-252,306	N/A
12/31/2017	921,500	165,684	-195,744	-194,300	N/A
9/30/2017	872,771	136,604	31,026	32,163	N/A
6/30/2017	876,929	167,562	N/A	71,717	N/A
3/31/2017	741,590	94,037	N/A	97,949	N/A
12/31/2016	756,437	123,503	N/A	30,436	N/A
12/31/2015	376,033	-6,740	N/A	32,010	N/A
12/31/2014	166,549	10,133	N/A	-248,247	N/A

アナリストによる今後の成長予測

収入対貯蓄率: A091990の予測収益成長率 (年間63.3% ) は貯蓄率 ( 2.3% ) を上回っています。

収益対市場: A091990の収益 ( 63.3% ) はKR市場 ( 29.5% ) よりも速いペースで成長すると予測されています。

高成長収益: A091990の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: A091990の収益 ( 17.2% ) KR市場 ( 10% ) よりも速いペースで成長すると予測されています。

高い収益成長: A091990の収益 ( 17.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: A091990の自己資本利益率は、3年後には低くなると予測されています ( 13.7 %)。

Celltrion Healthcare 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 11%

Consensus forecasts updated

Consensus EPS estimates fall by 19%

Price target increased to ₩83,571

Consensus forecasts updated

Price target increased to ₩75,167

Recent updates

Celltrion Healthcare Co., Ltd.(KOSDAQ:A091990) dropped from FTSE All-World Index (USD)

Third quarter 2023 earnings released: EPS: ₩281 (vs ₩853 in 3Q 2022)

Celltrion Healthcare Presents Phase III Data from the LIBERTY-CD and LIBERTY-UC Clinical Trials

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

Consensus EPS estimates fall by 11%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 15%

Upcoming dividend of ₩130 per share

Consensus forecasts updated

Consensus EPS estimates fall by 19%

European Commission Approves Celltrion Healthcare’s Vegzelma (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer

Price target increased to ₩83,571

Consensus forecasts updated

Price target increased to ₩75,167

Price target decreased to ₩69,333

Price target decreased to ₩78,311

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Celltrion Group Announces Positive Results for Its Cocktail Therapy Candidates Including Neutralisation Data Against Omicron Variant

Price target decreased to ₩99,889

Celltrion Accelerates Development of Nebulised Cocktail Therapy (CT-P63 in Combination with CT-P59) Using Its Antibody Platform to Tackle New Covid-19 Variants

Price target decreased to ₩109,900

Price target decreased to ₩127,200

Investor sentiment deteriorated over the past week

Celltrion Receives Approval from Korean Ministry of Food and Drug Safety for regdanvimab

Consensus EPS estimates fall to ₩1,997

Celltrion’S Monoclonal Antibody Treatment for COVID-19, Regdanvimab, Demonstrates Strong Neutralising Activity Against Delta Variant

Celltrion Healthcare Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59), an Anti-Covid-19 Monoclonal Antibody Treatment

Celltrion Healthcare Presents Positive One-Year Data for YuflymaTM (Ct-P17)

Consensus EPS estimates fall to ₩2,086

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)

Celltrion Healthcare Receives Positive Chmp Opinion for Subcutaneous Formulation of Infliximab, Remsima® Sc, for Direct Use of Subcutaneous Therapy Without Iv Loading in Adults with Rheumatoid Arthritis

New 90-day low: ₩120,700

Celltrion Healthcare Receives European Commission Approval for the First High Concentration, Low-Volume and Citrate-Free Biosimilar Adalimumab, YuflymaTM

Price target raised to ₩131,030

New 90-day high: ₩176,900

Celltrion Healthcare Receives EU CHMP Positive Opinion for Biosimilar Adalimumab, CT-P17

New 90-day high: ₩108,100

Celltrion Healthcare Presents Positive Top-Line Efficacy and Safety Results for CT-P17 in the Treatment of Rheumatoid Arthritis

New 90-day low: ₩84,700

Celltrion Initiates Post-Exposure Prophylaxis Clinical Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59

Celltrion Healthcare Announces Two New Data Sets Relating to the Use of the Subcutaneous Formulation of Infliximab, Remsima

New 90-day low: ₩94,200

Celltrion Receives Korean MFDS Approval to Initiate Phase Ii/Iii Pivotal Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘